CD33 and cancer: A monoclonal anti-CD33 antibody (gemtuzumab), against a surface marker of human myeloid cells, conjugated with a toxin (ozogamicin) has successfully depleted the CD33-expressing MDSCs and restored the capacity of T cell immunity and immunotherapy against cancers in clinical trials66.